Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02810704 · ClinicalTrials.gov registry record · Phase 4

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
Phase 4
Development phase
18,883
Enrollment target

NCT02810704 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18,883 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02810704, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
18,883 participants
Enrollment target

Study Summary

PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.

Interventions

  • DRUG Warfarin
  • DRUG Rivaroxaban
  • DRUG Enteric Coated Aspirin

Trial Details

FieldValue
Enrollment Target 18,883 participants
Start Date 2016-12
Est. Completion 2025-09
Phase Phase 4

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

What the Registry Record Tells You About NCT02810704

The ClinicalTrials.gov registry entry for NCT02810704 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18,883 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.

NCT02810704 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02810704 about?

NCT02810704 is a clinical study titled "Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement". PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban...

What is the current status of trial NCT02810704?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 18,883 participants. The study started on 2016-12. Estimated completion is 2025-09.

What interventions are being tested in trial NCT02810704?

The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (DRUG), Enteric Coated Aspirin (DRUG).

Who is sponsoring clinical trial NCT02810704?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.